Novo Nordisk A/S (NYSE:NVO) Cut to "Buy" at StockNews.com

Novo Nordisk A/S (NYSE:NVO - Get Free Report) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a research report issued to clients and investors on Tuesday.

Other analysts have also recently issued research reports about the stock. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. BMO Capital Markets cut their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research report on Monday, December 23rd. UBS Group upgraded shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. Finally, Morgan Stanley initiated coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an "equal weight" rating on the stock. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $135.00.

Novo Nordisk A/S Price Performance

Shares of NVO traded down $4.89 during mid-day trading on Tuesday, reaching $57.99. The company had a trading volume of 32,192,935 shares, compared to its average volume of 5,975,692. The company's 50 day simple moving average is $75.52 and its 200 day simple moving average is $91.71. The company has a market capitalization of $260.23 billion, a price-to-earnings ratio of 17.63, a P/E/G ratio of 0.90 and a beta of 0.61. Novo Nordisk A/S has a 1-year low of $57.28 and a 1-year high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of institutional investors have recently made changes to their positions in the stock. Center for Financial Planning Inc. raised its position in Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares during the period. Strategic Investment Solutions Inc. IL increased its position in shares of Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after buying an additional 300 shares during the period. Park Square Financial Group LLC bought a new position in shares of Novo Nordisk A/S in the 4th quarter worth approximately $29,000. Transce3nd LLC bought a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at $33,000. Finally, CX Institutional purchased a new stake in shares of Novo Nordisk A/S in the 1st quarter worth approximately $36,000. Institutional investors own 11.54% of the company's stock.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.